// App-Quantinova.ai

LB520 : A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380

Researchers

Presenter

  • Manish Patel

Principal Investigators

  • Kathleen N. Moore

  • Desiree Piscitello

  • Jayesh Majithiya

  • Marina Roy Luzarraga

  • Helen Millward

  • Sarah V. Holt

  • Melissa Johnson

Medical Centers

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, OK

  • Artios Pharma, Cambridge, United Kingdom

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Ataxia telangiectasia

  • Solid malignancies

  • Seizures sensorineural deafness ataxia mental retardation electrolyte imbalance

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT04657068

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved